Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.27 is 19% below its 2-year average of 0.33, around the middle of its 2-year range (0.00–0.65).
As of the fiscal period ended Tuesday, June 30, 2026. 33.38% below its 12-month average of 0.40.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.27.
DEBT TO EQUITY RATIO
0.27
DEBT TO EQUITY RATIO AVG TTM
0.40
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-33.38%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 520 covered companies
CURRENT VS SECTOR MEDIAN
+98.60%
vs the sector median at left
Market Cap
$4.70B
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$4.64B
Debt to Equity Ratio
0.14
TTM Avg
0.24
3Y Avg
0.29
5Y Avg
0.27
Market Cap
$4.63B
Debt to Equity Ratio
0.04
TTM Avg
0.04
3Y Avg
0.07
5Y Avg
0.05
Market Cap
$4.81B
Debt to Equity Ratio
N/A
TTM Avg
1.21
3Y Avg
0.92
5Y Avg
0.62
Market Cap
$4.43B
Debt to Equity Ratio
2.87
TTM Avg
0.86
3Y Avg
0.57
5Y Avg
0.43
Market Cap
$4.39B
Debt to Equity Ratio
N/A
TTM Avg
3.41
3Y Avg
2.92
5Y Avg
3.07
Market Cap
$4.37B
Debt to Equity Ratio
0.10
TTM Avg
0.07
3Y Avg
0.07
5Y Avg
0.07
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BillionToOne, Inc. (BLLN) | $4.69B | 0.27 | 0.40 | N/A | N/A |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.70B | 0.00 | 0.00 | 0.00 | 0.00 |
| LifeStance Health Group, Inc. (LFST)vs › | $4.64B | 0.14 | 0.24 | 0.29 | 0.27 |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.63B | 0.04 | 0.04 | 0.07 | 0.05 |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.81B | N/A | 1.21 | 0.92 | 0.62 |
| Erasca, Inc. (ERAS)vs › | $4.88B | 0.12 | 0.13 | 0.14 | 0.11 |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.43B | 2.87 | 0.86 | 0.57 | 0.43 |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.39B | N/A | 3.41 | 2.92 | 3.07 |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.37B | 0.10 | 0.07 | 0.07 | 0.07 |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.03B | 0.80 | 0.31 | 0.29 | 0.31 |
Debt/Equity
0.27
Current Ratio
11.69
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.27 |
| 2026-03-31 | 0.29 |
| 2025-12-31 | 0.23 |
| 2025-09-30 | 0.60 |
| 2025-06-30 | 0.63 |
| 2025-03-31 | 0.63 |
| 2024-12-31 | 0.65 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 0.00 |
